Catalio Capital Management, LP Blueprint Medicines Corp Call Options Transaction History
Catalio Capital Management, LP
- $457 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BPMC
# of Institutions
379Shares Held
65.9MCall Options Held
1.6MPut Options Held
1.41M-
Vanguard Group Inc Valley Forge, PA6.77MShares$627 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$615 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.68MShares$525 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA4.28MShares$396 Million0.07% of portfolio
-
State Street Corp Boston, MA2.5MShares$231 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.52B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...